NLRC4-MAS
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension (NCT03512314) | AB2 Bio Ltd. | 2018-01-24 |
| Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (NCT03113760) | AB2 Bio Ltd. | 2017-07-21 |
| Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases) (NCT02974595) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-12-09 |
Track NLRC4-MAS automatically
Every clearance here is in the API, with alerts when new ones post.